Geode Capital Management LLC Buys 682,273 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

Geode Capital Management LLC lifted its holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 23.7% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,562,758 shares of the company's stock after buying an additional 682,273 shares during the quarter. Geode Capital Management LLC owned about 1.74% of Taysha Gene Therapies worth $7,163,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Creative Planning bought a new stake in shares of Taysha Gene Therapies during the third quarter valued at approximately $28,000. Principal Financial Group Inc. bought a new position in Taysha Gene Therapies in the 2nd quarter valued at $48,000. China Universal Asset Management Co. Ltd. increased its stake in shares of Taysha Gene Therapies by 79.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 39,417 shares of the company's stock valued at $79,000 after buying an additional 17,446 shares during the period. Intech Investment Management LLC bought a new stake in shares of Taysha Gene Therapies during the third quarter worth $85,000. Finally, Scientech Research LLC acquired a new position in shares of Taysha Gene Therapies during the second quarter valued at $97,000. Institutional investors own 77.70% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have weighed in on TSHA. Needham & Company LLC reissued a "buy" rating and set a $6.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Chardan Capital reissued a "buy" rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research note on Thursday, November 14th. Canaccord Genuity Group raised their price objective on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the company a "buy" rating in a research note on Friday, November 15th. JMP Securities reiterated a "market outperform" rating and set a $5.00 target price on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $6.63.

Taysha Gene Therapies Trading Up 3.8 %

Shares of TSHA traded up $0.07 during trading hours on Friday, reaching $1.92. The stock had a trading volume of 1,281,974 shares, compared to its average volume of 1,526,037. The firm has a 50-day moving average of $2.10 and a 200 day moving average of $2.18. The company has a quick ratio of 5.51, a current ratio of 5.51 and a debt-to-equity ratio of 0.48. The company has a market cap of $393.49 million, a P/E ratio of 3.05 and a beta of 0.79. Taysha Gene Therapies, Inc. has a 52 week low of $1.19 and a 52 week high of $4.32.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.